Pierre Gagnon - 29 Sep 2023 Form 3 Insider Report for NKGen Biotech, Inc. (NKGN)

Role
Chief Operating Officer
Signature
/s/ Pierre Gagnon, Attorney-in-fact
Issuer symbol
NKGN
Transactions as of
29 Sep 2023
Net transactions value
$0
Form type
3
Filing time
10 Oct 2023, 16:11:58 UTC
Next filing
14 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NKGN Stock Option (right to buy) 29 Sep 2023 Common Stock 11,353 $0.3200 Direct F1, F2
holding NKGN Stock Option (right to buy) 29 Sep 2023 Common Stock 150,481 $6.67 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is fully vested and exercisable.
F2 Mr. Gagnon was appointed as Chief Operating Officer of the Issuer effective immediately after the Effective Time (as defined in the Business Combination Agreement, dated April 14, 2023 (the "Business Combination Agreement"), by and among the Issuer, Austria Merger Sub, Inc., and NKGen Biotech, Inc.). In connection with the Closing (as defined in the Business Combination Agreement) and prior to being appointed an executive officer of the Issuer, Mr. Gagnon exchanged his options to acquire shares of common stock of NKGen Biotech, Inc. for options to acquire shares of the Issuer.
F3 One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of November 1, 2021, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Remarks:

See attached Exhibit 24 - Power of Attorney